Key Takeaways Accelerated global expansion and rapid market adoption are fueled by strong partnerships, clear patient targeting, and proactive payer and clinician engagement. Multiple near-term clinical advancements and pipeline synergies position Agios for transformative revenue growth and margin improvement, surpassing standard industry progress.Read more
Key Takeaways New product launches and regulatory milestones are set to expand market reach and generate multiple long-term revenue streams. Strategic international partnerships and innovation in rare disease therapies enhance profitability and create sustained growth opportunities.Read more
Key Takeaways Increasing payer pressure and regulatory demands threaten Agios' pricing power, revenue growth, and development timelines amid broader drug affordability concerns. Heavy reliance on a single product and concentrated pipeline exposes Agios to outsized risks from competition, clinical setbacks, and potential economic downturns.Read more
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
